

# Melanoma Requisition to PET Centre

## TO BE COMPLETED BY THE REFERRING PHYSICIAN

The indications under Section B are part of the Ontario PET Registry. Completion of a post scan form is required following the PET scan. Together the pre and post scan information will provide vital data to build evidence for use of PET for this indication. Accurately complete both the pre and post scan forms.

Referring Physician Name: \_\_\_\_\_

Physician Phone: ( \_\_\_\_\_ ) \_\_\_\_\_ ext. \_\_\_\_\_ Fax: ( \_\_\_\_\_ ) \_\_\_\_\_ CPSO No: \_\_\_\_\_

Patient Name: \_\_\_\_\_  
SURNAME FIRST NAME MIDDLE

OHIP Number: \_\_\_\_\_

Telephone: ( \_\_\_\_\_ ) \_\_\_\_\_ Postal Code: \_\_\_\_\_

Date of birth: \_\_\_\_\_ / \_\_\_\_\_ / \_\_\_\_\_ Gender: ☐ M ☐ F ☐ Other  
YYYY / MM / DD

### Relevant Clinical History:

Provide the most recent and relevant imaging report(s) and other relevant clinical history.

The following documents must be attached to this requisition:

- ☐ Relevant Imaging Studies within the previous 3 months (i.e. CT, US, MR, Other)
- ☐ Consult Note or Referral Letter; including relevant lab work/pathology, if relevant

### Fax Instructions

Please fax the completed request form, along with the required supporting documentation, to the PET Centre of choice for appointment. A complete list of PET Centres and their contact information is available at [PET Centre Locations List | CCO Health](#)

Complete EITHER Section A or B (not both)

**Section A** – PET for the staging of patients with localized “high risk” melanoma, or for the evaluation of patients with isolated melanoma metastases, when surgery or other ablative therapies are being considered.

**Indication** (choose only one)

- ☐ Staging of localized high risk melanoma  
(e.g., lymph node metastases, satellitosis or intransit metastases, or deep head & neck melanoma)
- ☐ Evaluation of isolated metastases

Attach the relevant diagnostic imaging reports (CT, US, MRI) & provide images to PET centre.

Physician Signature: \_\_\_\_\_ Date: \_\_\_\_\_

# Melanoma Requisition to PET Centre

TO BE COMPLETED BY THE REFERRING PHYSICIAN

Complete EITHER Section A or B (not both)

Patient Name: \_\_\_\_\_

## \*Section B – PET in Immunotherapy for Metastatic Melanoma

### Melanoma Demographics

Type of Melanoma: ☐ Cutaneous ☐ Mucosal ☐ Acral Lentiginous ☐ Uveal ☐ Unknown Primary  
BRAF Status: ☐ Wild Type ☐ Mutant ☐ Other molecular change (specify): \_\_\_\_\_  
Current line of Immunotherapy: ☐ First Line ☐ Second Line ☐ Other (specify): \_\_\_\_\_  
Has the patient received prior adjuvant immunotherapy? ☐ Yes ☐ No

### Indication (choose only one)

☐ \*Baseline Staging – PET for the baseline staging of patients prior to starting immunotherapy; or for patients who are receiving immunotherapy and have not previously had a baseline PET. (choose one)

- ☐ Baseline PET **PRIOR** to patients starting immunotherapy  
☐ Baseline PET for patients who are receiving immunotherapy, and have not previously had a Baseline PET

☐ \*Response Assessment – PET for response assessment of patients with metastatic melanoma currently receiving immunotherapy.

Reason for PET: ☐ Early Response Assessment (choose one): ☐ After 2 cycles ☐ After 3 cycles ☐ After 4 cycles  
☐ End of Therapy Response Assessment (specify reason):  
☐ Therapy Complete ☐ Adverse Event ☐ Patient Decision  
☐ Radiographic Complete Response or Good Partial Response  
☐ Other (specify): \_\_\_\_\_

Immunotherapy Start Date: \_\_\_\_\_ YYYY-MM-DD Date of most recent Immunotherapy dose: \_\_\_\_\_ YYYY-MM-DD

Current Immunotherapy Regimen (select all that apply):

- ☐ Anti PD1 Monotherapy ☐ Anti CTLA-4 Monotherapy ☐ Anti PD1 & Anti CTLA-4 combination therapy  
☐ Other (specify): \_\_\_\_\_

Baseline PET scan available for comparison? ☐ No ☐ Yes (specify date): \_\_\_\_\_ YYYY-MM-DD

Residual Lesion(s) on CT?

- ☐ Not Applicable (no CT available)  
☐ No  
☐ Yes (specify total number & locations): Number of lesions: ☐ 1 ☐ 2 ☐ 3 ☐ ≥ 4  
Location of lesions: ☐ Lung ☐ Liver ☐ Bone ☐ Adrenal ☐ Brain  
☐ Other (specify): \_\_\_\_\_

Does patient have clinical evidence of immune related adverse event(s)?

- ☐ No  
☐ Yes (select all that apply): ☐ Enterocolitis ☐ Fatigue ☐ Hematological ☐ Hepatitis ☐ Hypophysitis  
☐ Pancreatitis ☐ Rash ☐ Pneumonitis ☐ Peripheral neuropathy  
☐ Sarcoidosis ☐ Thyroiditis ☐ Other (specify): \_\_\_\_\_

**Melanoma Requisition to PET Centre**  
**TO BE COMPLETED BY THE REFERRING PHYSICIAN**

**Complete EITHER Section A or B (*not both*)**

**Patient Name:** \_\_\_\_\_

**\*Section B (continued) – PET in Immunotherapy for Metastatic Melanoma**

**Select Management Plan – if PET were NOT available, what is your Current Management Plan**

Pre-PET Treatment Plan (select all that apply):

- |  |   |
|--|---|
| <input type="checkbox"/> Start Immunotherapy (specify):                                      | <input type="checkbox"/> Anti PD1 Monotherapy                       |
|  | <input type="checkbox"/> Anti PD1 & Anti CTLA-4 combination therapy |
|  | <input type="checkbox"/> Anti CTLA-4 Monotherapy                    |
|  | <input type="checkbox"/> Other (specify): _____                     |
| <br>   |   |
| <input type="checkbox"/> Continue Immunotherapy  |   |
| <input type="checkbox"/> Discontinue Immunotherapy   |   |
| <input type="checkbox"/> Surgery   |   |
| <input type="checkbox"/> Targeted Therapy  |   |
| <input type="checkbox"/> Clinical Trial, (specify the protocol or SOC Name or Number): _____ |   |
| <input type="checkbox"/> Radiation   |   |
| <input type="checkbox"/> Chemotherapy, (specify both regimen & number of cycles):            | a. Regimen _____  |
|  | b. Number of Cycles: _____  |
| <input type="checkbox"/> Other, please describe _____  |   |

**Physician Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_